Novavax director gets equity awards, RSUs convert

Novavax director David M. Mott reported equity compensation and an RSU vesting event.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Novavax director David M. Mott reported equity compensation and an RSU vesting event. On June 18, 2026, he received grants of 14,180 Restricted Stock Units and a stock option for 21,270 shares of common stock with a $9.13 exercise price. Both awards vest 100% on the first anniversary of the grant date, subject to his continued service on the Board.

On June 20, 2026, 18,880 previously granted RSUs fully vested and were converted into 18,880 shares of Novavax common stock. Following this conversion, he directly holds 79,770 shares of common stock. These transactions reflect compensation-related awards and an option-style RSU conversion, with no open-market buying or selling.

Insider Trade Summary

18,880 shares exercised/converted

Exercise 4 txns

Insider MOTT DAVID M

Role Director

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	18,880	$0.00	$0.00
Exercise	Common Stock	18,880	$0.00	$0.00
Grant/Award	Stock Option (Right to Buy)	21,270	$0.00	$0.00
Grant/Award	Restricted Stock Units	14,180	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 21,270 contracts (Direct); Restricted Stock Units — 14,180 contracts (Direct); Common Stock — 79,770 shares (Direct)

Footnotes (4)

F1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2. One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F3. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.
F4. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date.

Key Figures

RSU grant: 14,180 units Stock option grant: 21,270 shares Option exercise price: $9.13 per share +3 more

6 metrics

RSU grant 14,180 units Restricted Stock Units granted on June 18, 2026

Stock option grant 21,270 shares Option on common stock granted on June 18, 2026

Option exercise price $9.13 per share Exercise price for 21,270-share stock option

Option expiration June 18, 2036 Expiration date of new stock option grant

RSUs converted 18,880 units RSUs vested and converted to common stock on June 20, 2026

Common shares held 79,770 shares Direct Novavax common stock holdings after RSU conversion

Key Terms

Restricted Stock Units, Stock Option (Right to Buy), Amended and Restated 2015 Stock Incentive Plan, vesting

4 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents a contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy) for 21,270 underlying shares of Common Stock"

Amended and Restated 2015 Stock Incentive Plan financial

"option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest"

vesting financial

"One hundred percent (100%) of the RSUs subject to this grant will vest on the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Novavax (NVAX) director David M. Mott receive?

David M. Mott received a grant of 14,180 Restricted Stock Units and a stock option covering 21,270 shares. Both awards were granted at a zero grant price as part of Novavax’s Amended and Restated 2015 Stock Incentive Plan.

What is the exercise price and term of David M. Mott’s new Novavax stock options?

Mott’s new stock option covers 21,270 Novavax common shares at an exercise price of $9.13 per share. The option expires on June 18, 2036, providing a long-dated equity incentive tied to the company’s future stock performance.

When do David M. Mott’s recent Novavax equity awards vest?

Both the 14,180 RSUs and the stock option for 21,270 shares vest 100% on the first anniversary of the June 18, 2026 grant date. Vesting requires continued service on Novavax’s Board of Directors through that vesting date.

What happened to David M. Mott’s previously granted Novavax RSUs?

On June 20, 2026, 18,880 previously granted RSUs fully vested and converted into 18,880 Novavax common shares. After this conversion, Mott’s RSU balance from that grant dropped to zero, and his direct common stock holdings increased accordingly.

How many Novavax shares does David M. Mott hold after these transactions?

After the June 20, 2026 RSU conversion, David M. Mott directly holds 79,770 shares of Novavax common stock. This total reflects equity previously accumulated plus the 18,880 shares received when his vested RSUs converted into common stock.

Do David M. Mott’s Form 4 transactions in Novavax involve open-market buying or selling?

The reported transactions consist of equity grants and an RSU conversion into common shares, with no open-market purchases or sales. The codes show derivative exercises and awards, indicating compensation-related activity rather than discretionary trading in Novavax stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/23/2026 - 07:51 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MOTT DAVID M

(Last)

(First)

(Middle)

21 FIRSTFIELD ROAD

(Street)

GAITHERSBURG

MARYLAND

20878

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NOVAVAX INC [ NVAX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/20/2026		M		18,880	A	⁽¹⁾	79,770	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$9.13	06/18/2026		A		21,270		⁽²⁾	06/18/2036	Common Stock	21,270	$0	21,270	D
Restricted Stock Units	⁽¹⁾	06/18/2026		A		14,180		⁽³⁾	⁽³⁾	Common Stock	14,180	$0	14,180	D
Restricted Stock Units	⁽¹⁾	06/20/2026		M			18,880	⁽⁴⁾	⁽⁴⁾	Common Stock	18,880	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.

2. One hundred percent (100%) of the shares subject to this option grant under the Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

3. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, will vest on the first anniversary of the June 18, 2026 grant date subject to continued service on the Company's Board of Directors through the vesting date.

4. One hundred percent (100%) of the RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested on the first anniversary of the June 20, 2025 grant date subject to continued service on the Company's Board of Directors through the vesting date.

	/s/ Mark J. Casey, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR